Trevena, Inc.
American biopharmaceutical company
Trevena, Inc. is an American biopharmaceutical company focused on the development of novel therapeutics for the treatment of central nervous system (CNS) disorders. The company is headquartered in Chesterbrook, Pennsylvania.
History[edit | edit source]
Trevena, Inc. was founded in 2007 by a team of scientists from Duke University and other institutions. The company was established to leverage new insights into G protein-coupled receptors (GPCRs) to develop innovative therapies. Trevena went public in 2014, listing on the NASDAQ under the ticker symbol TRVN.
Research and Development[edit | edit source]
Trevena's research focuses on the development of biased ligands for GPCRs, which are designed to selectively activate specific signaling pathways. This approach aims to improve the therapeutic profile of drugs by enhancing efficacy and reducing side effects.
Oliceridine[edit | edit source]
One of Trevena's lead products is oliceridine, a novel opioid analgesic designed to provide pain relief with fewer side effects compared to traditional opioids. Oliceridine acts as a biased ligand at the mu-opioid receptor, preferentially activating the G protein pathway over the beta-arrestin pathway, which is associated with many of the adverse effects of opioids.
Other Pipeline Products[edit | edit source]
Trevena is also developing other CNS-targeted therapies, including TRV734, a follow-up to oliceridine, and TRV250, a treatment for migraine. These compounds are in various stages of clinical development.
Business Strategy[edit | edit source]
Trevena's business strategy involves advancing its pipeline through clinical trials and seeking strategic partnerships to support the commercialization of its products. The company aims to address unmet medical needs in pain management and other CNS disorders.
Corporate Governance[edit | edit source]
Trevena is governed by a board of directors with extensive experience in the pharmaceutical and biotechnology industries. The company's leadership team includes experts in drug development, regulatory affairs, and business operations.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
